ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02383368
Recruitment Status : Completed
First Posted : March 9, 2015
Last Update Posted : May 11, 2018
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132. The study will also determine the pharmacokinetics (PK) of ASP4132 and evaluate the preliminary antitumor activity.

Condition or disease Intervention/treatment Phase
Lymphoma Refractory Solid Tumors Advanced Cancer Drug: ASP4132 Phase 1

Detailed Description:
The study consists of two parts and these will be conducted sequentially: Part 1 (dose escalation) and Part 2 (dose expansion). Subjects will participate in Part 1 or Part 2.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 165 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Dose-escalation/Expansion, Phase 1 Study of ASP4132, Given Orally to Subjects With Advanced Refractory Solid Tumors and Lymphoma
Actual Study Start Date : March 23, 2015
Actual Primary Completion Date : April 27, 2018
Actual Study Completion Date : April 27, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: ASP4132 dose escalation

Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:

Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off.

Drug: ASP4132
oral

Experimental: ASP4132 dose expansion
Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
Drug: ASP4132
oral




Primary Outcome Measures :
  1. Safety as assessed by adverse events [ Time Frame: up to 39 months ]
  2. Safety as assessed by clinical laboratory tests [ Time Frame: up to 39 months ]
  3. Safety as assessed by vital signs [ Time Frame: up to 39 months ]
  4. Safety as assessed by electrocardiograms (ECG) [ Time Frame: up to 39 months ]

Secondary Outcome Measures :
  1. Objective response rate to ASP4132 [ Time Frame: Week 16 ]
  2. Duration of response to ASP4132 [ Time Frame: Week 16 ]
  3. Disease control rate to ASP4132 [ Time Frame: Week 16 ]
  4. Pharmacokinetic profile of ASP4132: Cmax, tmax, AUClast, AUC24, AUCinf, t1/2, accumulation ratio, CL/F, Vz/F [ Time Frame: up to 43 days ]
    Maximum concentration (Cmax), the time after dosing when Cmax occurs (tmax), AUC from the time of dosing to the last measurable concentration (AUClast), AUC from the time of dosing to 24 hours (AUC24), from the time of dosing extrapolated to time infinity (AUCinf), Apparent Terminal Elimination Half-life (t1/2), apparent total systemic clearance after single or multiple extravascular dosing (CL/F), apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing (Vz/F)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a life expectancy of more than 3 months
  • Subject agrees not to participate in another interventional study while on treatment.
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  • Female subject must be either:

    1. Of non-child bearing potential:

      • post-menopausal (defined as at least 1 year without any menses) prior to Screening,
      • or, documented surgically sterile or status post hysterectomy
    2. Or, if of childbearing potential,

      • agree not to try to become pregnant during the study and for 90 days after the final study drug administration;
      • if heterosexually active must use two forms of birth control
  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
  • Subject must have advanced and/or metastatic, histologically or cytologically documented cancer or lymphomas, for whom there is no available standard therapy shown to provide clinical benefit.

Exclusion Criteria:

  • Subject has absolute neutrophil count < 1000/μL, platelet count < 75,000/μL, and hemoglobin < 8 g/dL (< 5 mmol/L) at Screening
  • Subject has total serum bilirubin ≥1.5 times the upper limit of normal (ULN),serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 times ULN, or albumin ≤ 3.0 g/dL at Screening.
  • Subject has any abnormalities in serum sodium, potassium, chloride, calcium and magnesium levels ≥ Grade 2 at screening (CTCAE Version 4.03).
  • Subject has a known elevation in serum lactate at screening ˃ 2x institutional ULN
  • Subject has an estimated glomerular filtration rate (eGFr) of < 60ml/min as calculated by the modification of diet Renal disease (MDRD) Equation.
  • Subject with a QTcF of > 450 msec in male subjects and > 470 msec in female subjects on the screening 12 lead ECG.
  • Subject has Neuropathy ≥ Grade 2 at Screening.
  • Subject has Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus and currently being treated with insulin or sulfonylureas.
  • Subject has concomitant active second malignancies unless remission was achieved at least 3 years prior to study entry and subject is no longer on therapy for the malignancy.
  • Subject has a significant cardiovascular disease
  • Subject has a known history of acute or chronic hepatitis B (HBV), HIV or hepatitis C (HCV) infection.
  • Subject has serious/active bacterial, viral or fungal infection requiring systemic treatment.
  • Subject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation.
  • Subject has active central nervous system (CNS) metastases not controlled by prior surgery or radiotherapy (subjects must be off steroids). Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by brain MRI/CT.
  • Subject has concurrent severe or uncontrolled medical disease or organ system dysfunction which, in the opinion of the Investigators, would limit life expectancy to < 3 months.
  • Subject has psychiatric disorder or altered mental status that would preclude an understanding of the informed consent process and/or completion of the necessary study procedures.
  • Subject has difficulty swallowing large pills.
  • Subject currently being treated with biguanides or other agents known to increase risk of lactic acidosis.
  • Subject has unavoidable concomitant treatment with any drug known for causing Torsades de Pointes.
  • Subject has had radiotherapy or surgery within the 4 weeks prior to treatment with ASP4132.
  • Subject has not discontinued all previous systemic therapies for cancer including chemotherapy, immunotherapy, or biological therapies for at least 14 days prior to the initiation of ASP4132.
  • Subject has not fully recovered from the acute toxicities (except alopecia) of any prior anti-cancer therapy.
  • Subject requiring concomitant use of strong CYP3A4 inhibitors or inducers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02383368


Locations
United States, Connecticut
Site US10001
New Haven, Connecticut, United States, 06520
United States, Illinois
Site US10004
Chicago, Illinois, United States, 60637
United States, Minnesota
Site US10002
Rochester, Minnesota, United States, 55905
United States, Texas
Site US10003
Houston, Texas, United States, 77030
United States, Virginia
Site US10005
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
Study Director: Medical Director Astellas Pharma Global Development, Inc.

Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT02383368     History of Changes
Other Study ID Numbers: 4132-CL-0001
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: May 11, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
Pharmacokinetics
ASP4132
Lymphoma
Refractory Solid Tumors

Additional relevant MeSH terms:
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases